Mar 28 |
Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023
|
Mar 28 |
Pulse Biosciences files for $50M mixed securities shelf
|
Mar 28 |
Pulse Biosciences to initiate rights offering
|
Mar 28 |
Pulse Biosciences GAAP EPS of -$0.22
|
Mar 28 |
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
|
Mar 28 |
Pulse Biosciences Announces Plans to Initiate a Rights Offering
|
Mar 28 |
Earnings Scheduled For March 28, 2024
|
Mar 14 |
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
|
Mar 8 |
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
|
Feb 14 |
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
|